Duke University, through its Duke Clinical Research Institute (DCRI), has entered into a collaboration with Bristol-Myers Squibb (BMS) to promote open access to clinical information from company-sponsored studies.

The purpose of the collaboration is to support BMS’s efforts at expanded transparency and leverage existing resources for scientific discovery and improve public health, according to the company. BMS’s efforts will increase access to a broader set of clinical trial information from in-scope, company-sponsored studies and enable independent scientific review through DCRI of requests from researchers that meet pre-specified requirements. The DCRI will also review the final manuscripts produced from the data for scientific integrity and consistency with the original proposed work.

Register or login for access to this item and much more

All Health Data Management content is archived after seven days.

Community members receive:
  • All recent and archived articles
  • Conference offers and updates
  • A full menu of enewsletter options
  • Web seminars, white papers, ebooks

Don't have an account? Register for Free Unlimited Access